Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: We appreciate this opportunity to
clarify and expand our results. In response to concerns that the patterns
of hormone use in our patient population were atypical, we note that among
hormone users in our study the percentage of person-years associated with
estrogen-progestin use increased from 7% to 37% from 1979-1983 to 1992-1995.
The figure for the later period compares with results from a nationally representative
cohort in which 31% of women interviewed in 1992 who had used HRT received
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-Progestin Replacement and Risk of Breast Cancer—Reply. JAMA. 2000;284(6):691-694. doi:10.1001/jama.284.6.691